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Renal handling of silicon in normals and patients with renal insuffi-
ciency. We have compared the renal handling of silicon in 16 patients
with renal insufficiency to 14 normal individuals. Silicon, phosphate and
creatinine were measured in plasma and urine samples. The renal
insufficiency group showed significant increases in plasma silicon (1.28
0.19 vs. 0.17 0.03 mg/liter), creatinine (5.19 0.85 vs. 0.89 0.03
mg/dl) and phosphate (1.33 0.11 vs. 1.07 0.4 mmol/liter). Fractional
phosphate excretion was increased in the renal insufficiency group (0.55
0.07 vs. 0.14 0.01). In contrast, the fractional excretion of
ultrafiltrable silicon was not significantly different between groups (0.78
0.07 vs. 0.87 0.06). It is concluded that renal insufficiency does not
alter the tubular handling of silicon and that regulatory control of silicon
excretion is unlikely.
Although it is agreed that the urinary excretion of silicon
plays a major role in the regulation of silicon metabolism, there
is relatively sparse information concerning the renal handling of
silicon. Adler and Berlyne found an 86% fractional excretion of
silicon in normal individuals which increased to 111% in pa-
tients with chronic renal failure [1]. The presence of suppres-
sive interferences in their silicon assay, however, raises ques-
tions about the accuracy of their data [2].
The availability of an improved method for silicon analysis [3]
prompted us to reexamine the urinary excretion of silicon in
normals and patients with renal insufficiency. Our data show
similar fractional silicon excretion rates in both normal con-
trols, and individuals with renal failure. No evidence of regu-
latory control was observed.
Methods
We obtained blood and simultaneous urine samples from 16
(11 males, 5 females) patients with known renal insufficiency
during their outpatient visits to the Nephrology clinic at The
University of North Carolina Hospitals. We chose study sub-
jects who had chronic renal insufficiency with relatively stable
renal function. All subjects denied the use of over-the-counter
medications and gave informed consent to the phlebotomy
procedure. At time of study, 15 of the 16 patients with renal
insufficiency were receiving antihypertensive medication (Fu-
rosemide, 8; Clonidine, 7; calcium channel blockers, 5; angio-
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tensin converting inhibitors, 4; and beta blockers, 3). The
majority of patients (11/16) had biopsy-proven glomerular dis-
ease. This included three patients with focal segmental glomer-
uloscierosis, four with glomerulonephritis associated with vas-
culitic processes, two patients with lupus nephritis, one patient
with membranous glomerulonephritis, and one patient with
hereditary nephritis. Nonbiopsied patients included two with
the clinical diagnosis of diabetic nephropathy, two with ne-
phrotic syndrome of uncertain etiology, and one with chronic
renal failure. As anticipated, all patients with a diagnosis of
renal insufficiency had serum creatinine concentrations that
were significantly higher than normal. Similar samples were
obtained from 14 individuals who felt well, denied acute and
chronic illness, and served as normal controls. All subjects
were in the post-absorptive state at the time of sampling.
Analytical methods
Blood was collected as described previously [3] in plastic
disposable syringes that had been extensively washed to re-
move silicon contamination. Blood was placed in disposable
polypropylene tubes containing EDTA, then centrifuged. The
plasma was removed with disposable polyethylene pipettes and
stored in disposable polypropylene tubes for further analysis.
We instructed patients and controls to collect a midstream
specimen of urine without touching the container rim. Urine
aliquots were stored at 5°C in disposable propylene tubes. All
materials used in the blood and urine collection procedures
were found to be silicon-free. Silicon measurements were
obtained by a heated graphite atomizer technique using atomic
absorption spectrometry with a Zeeman 3030 (Perkin Elmer,
Norwalk, Connecticut, USA) atomic absorption spectrometer.
This new methodology utilizes a diluent that eliminates matrix
interference. Phosphate and creatinine determinations in
plasma and urine were done by automated laboratory tech-
niques [4, 5]. The results are presented as mean SEM.
Fractional excretions of silicon and U/P ratios were calculated
using ultrafiltrable silicon values. We calculated the ultrafiltra-
ble values by multiplying measured plasma silicon by 0.78. This
value is the combined mean ultrafiltrable fraction from 23
patients during hemodialysis in which we had previously ob-
served a mean value of 0.79 0.02 [6], and nine normals with
a mean value of 0.75 0.06. We combined both groups after we
had ascertained that the differences between means were not
statistically significant. The normal ultrafiltrable values were
obtained by ultrafiltration of plasma through Centricon-3 filters,
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3000 molecular wt cutoff (Amicon, Beverly, Massachusetts,
USA). Student's (-test was used for comparison of different
groups.
Results
Figure 1 shows the plasma creatinine, silicon, and phosphate
values for the two groups. As anticipated, plasma creatinine
values were significantly elevated in the renal insufficiency
group. In addition, plasma silicon and plasma phosphate values
were increased significantly.
Figure 2 displays the interrelationship between plasma silicon
and plasma creatinine in the normal and renal insufficiency
groups. There is a general tendency for plasma silicon concen-
trations to increase with elevated plasma creatinine values.
Figure 3 displays the fractional excretions of ultrafiltrable
silicon and phosphate for both groups. As anticipated, the
fractional excretion of phosphate is increased significantly in
the renal insufficiency group. In contrast, both groups display
similar fractional silicon excretion rates.
Figure 4 displays the relationship between U/ultrafiltrable
silicon and U/P creatinine in normal controls and renal insuffi-
ciency patients. As anticipated, patients with renal insufficiency
display smaller U/P creatinine values than individuals with
normal renal function. Nevertheless, both groups show quali-
tatively similar interrelationships with most of the U/ultrafiltra-
ble silicon values in each group lying below the line of equiva-
lence for U/P creatinine.
Discussion
This study was undertaken to elucidate more information
concerning the renal handling of silicon. Overall, we find that
plasma silicon concentrations tend to increase in parallel with
increases in serum creatinine values. This physiologic behavior
— is consistent with the notion that filtration rate is a major
12 determinant of urinary excretion of silicon, and that chronic
renal insufficiency does not substantially alter the tubular
handling of silicon. In this context, we attribute the variability
in the relationship between plasma silicon and plasma creati-
nine to variable dietary loads of silicon. This hypothesis is
strengthened further by the absence of significant change in the
fractional excretion of silicon in the chronic renal insufficiency
and control groups.
An important qualification should be mentioned. It is now
well recognized that the endogenous creatinine clearance may
introduce a positive bias into the estimation of glomerular
filtration rate, especially in patients with renal insufficiency. It
is generally agreed, however, that this tendency is minimized
by a creatinine methodology that measures noncreatinine chro-
mogens as well as true creatinine [7]. This is the type of
creatinine methodology that was employed in this study. Al-
though a tendency to overestimate the filtration rate may have
been present, we believe it unlikely that this would have
masked our ability to see altered tubular silicon handling, since
our experimental protocol readily detected the change in tubu-
lar reabsorption of phosphate in our renal insufficiency patients.
Our results differ qualitatively from those of Adler and
Berlyne [I]. Their patients with renal insufficiency displayed a
29% increase in fractional silicon excretion, with one-third
having excretion rates consistent with tubular secretion. This
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Fig. 1. Plasma levels of creatinine, silicon, and phosphate in the normal () and renal insufficiency () groups.
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Fig. 2. interrelationship between plasma silicon and plasma creatinine
in normal controls (- - -) and renal insufficiency patients (U). The least
squares regression line is displayed (plasma Si = 0.19; plasma Cr +
0.16, r2 = 0.61).
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difference cannot be ascribed to our use of ultrafiltrable rather
that total plasma values to calculate fractional silicon excretion
rates. It should be recalled that the use of ultrafiltrable values
reduces the calculated silicon filtered loads and, thus, makes it
easier to produce apparent net secretion. It is also noteworthy
that Adler and Berlyne used creatinine clearances, as we did, to
measure glomerular filtration rates. Consequently, we must
look elsewhere to explain the discrepancy in these results.
Adler and Berlyne used 24-hour urine collection rather than the
spot urine samples we employed, so it is possible that unrec-
ognized circadian increases in the concentration of silicon in
plasma may have contributed inadvertently to the augmented
fractional silicon excretion rates they observed. Alternatively,
the differences between studies may be due to analytical
problems with the silicon methodology used by Adler and
Berlyne.
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